KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Aquestive Therapeutics (AQST) over the last 5 years, with Dec 2024 value amounting to -$0.51.

  • Aquestive Therapeutics' EPS (Weighted Average and Diluted) fell 7.69% to -$0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.71, marking a year-over-year decrease of 54.35%. This contributed to the annual value of -$0.51 for FY2024, which is 292.31% down from last year.
  • As of FY2024, Aquestive Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.51, which was down 292.31% from -$0.13 recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.13 during FY2023, and registered a low of -$1.85 during FY2021.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.51 (2024), whereas its average is -$0.59.
  • Per our database at Business Quant, Aquestive Therapeutics' EPS (Weighted Average and Diluted) spiked by 88.39% in 2023 and then slumped by 292.31% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.66 in 2020, then declined by 11.45% to -$1.85 in 2021, then spiked by 39.46% to -$1.12 in 2022, then soared by 88.39% to -$0.13 in 2023, then crashed by 292.31% to -$0.51 in 2024.